Protocol Ledger

NCT07378527 · Phase II/III · RECRUITING

Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria

Interventional Phase II/III clinical trial protocol NCT07378527 sponsored by Beijing InnoCare Pharma Tech Co in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-02-13 Enrollment: 344 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07378527
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)344 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07378527
Protocol FieldVerified Registry Value
NCT IdentifierNCT07378527
Consolidated Lead SponsorBeijing InnoCare Pharma Tech Co
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment344 participants (ESTIMATED)
Registered Start Date2026-02-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI